

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6239121

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
NICHOLAS MATTHEW BOULIS	07/30/2020
JONATHAN PATRICK RILEY	07/30/2020
RECEIVING PARTY DATA	
Name:	EMORY UNIVERSITY
Street Address:	1599 CLIFTON ROAD
Internal Address:	4TH FLOOR
City:	ATLANTA
State/Country:	GEORGIA
Postal Code:	30322
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	62292157
Application Number:	16075122
CORRESPONDENCE DATA	
Fax Number:	(503)595-5301
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	5035955300
Email:	athena.bubenik-hartley@klarquist.com
Correspondent Name:	KLARQUIST SPARKMAN, LLP
Address Line 1:	ONE WORLD TRADE CENTER
Address Line 2:	121 SW SALMON ST., SUITE 1600
Address Line 4:	PORTLAND, OREGON 97204
ATTORNEY DOCKET NUMBER:	6975-96414-11
NAME OF SUBMITTER:	SUSAN ALPERT SIEGEL, PH.D.
SIGNATURE:	/Susan Alpert Siegel/
DATE SIGNED:	08/06/2020
Total Attachments: 4	
source=96414-11 Assignment#page1.tif	
source=96414-11 Assignment#page2.tif	

source=96414-11 Assignment#page3.tif

source=96414-11 Assignment#page4.tif

ASSIGNMENT

WHEREAS, we, Nicholas Matthew Boulis, of Atlanta, GA, and Jonathan Patrick Riley, of Williamsville, NY, have invented a certain invention, with others, as described in the patent applications listed in Exhibit A (attached hereto), which applications are collectively referred to as "the patent applications."

WHEREAS, EMORY UNIVERSITY, a Georgia nonprofit corporation having a place of business at 1599 Clifton Road, 4th Floor, Atlanta, Georgia 30322, desires to acquire an interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, we, Nicholas Matthew Boulis and Jonathan Patrick Riley, hereby sell, assign, and transfer to EMORY UNIVERSITY, the full and exclusive right, title, and interest in and to said invention, the patent applications, and patent rights throughout the world, including foreign patent priority rights, the right to file and prosecute International Applications under the Patent Cooperation Treaty, and the right to file and prosecute applications under the European Patent Convention; said invention, the patent applications, and letters patent in this or any foreign country, and all corresponding non-provisional applications, divisions, continuations, continuations-in-part, reissues, and extensions thereof, to be held and enjoyed by EMORY UNIVERSITY, for its own use and benefit, and for its successors and assigns to the full end of the term for which letters patent may be granted by the United States or any foreign country, as fully and entirely as the same would have been held by us had this assignment and sale not been made, and covenant that we have full right so to do, and agree that we will communicate to EMORY UNIVERSITY, or its successors and assigns, any facts known to us respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing, and reissue applications, make all rightful oaths, and do everything possible to aid EMORY UNIVERSITY, its successors, and assigns to obtain and enforce proper patent protection for said invention in the United States or any foreign country.

We confirm that, at the time the invention was made, we were under an obligation to assign the invention to EMORY UNIVERSITY.

We hereby grant the law firm of Klarquist Sparkman, LLP, the power to insert on this Assignment any further information that may be necessary or desirable in order to comply with all applicable legal requirements, including the rules of the United States Patent and Trademark Office, for submitting and recording this document.

Executed at the place and date opposite our respective signatures below


Nicholas Matthew Boulis

At _____

(City and State)

on this ____ day of July 30, 2020.


STATE OF _____)
COUNTY OF _____) ss.

witness #1


5/11

Abby Burbank

witness #2


Mark Allen

This ____ day of _____, 20____, before me personally came the above-named Nicholas Matthew Boulis, who executed the foregoing instrument in my presence, and who acknowledged to me that this instrument was executed by Nicholas Matthew Boulis's own free will for the purpose set forth therein.

Notary Public For
My commission expires:

[SEAL]

Executed at: Buffalo, NY, this 30 day of July, 2020
(city and state)

Jonathan Patrick Riley
Jonathan Patrick Riley

Witnessed by: [Signature]
Name (Print): David Farmer
Address: 40 George Karl Boulevard
Williamsville, NY 14221
Date: 7.30.20

Witnessed by: [Signature]
Name (Print): Penelope B. Kravitz
Address: 40 George Karl Boulevard
Williamsville, NY 14221
Date: 7.30.20

ACCEPTED BY:

EMORY UNIVERSITY

By: [Signature]

Date: July 31, 2020

Name: Laura Fahey Fritts

Title: Chief IP Officer

EXHIBIT A - LIST OF PATENT APPLICATIONS

Title	Application No.	Filing Date	Country
INTRACEREBROVENTRICULAR DOSING REGIMEN FOR SINGLE STRANDED AND SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9, IN ORDER TO TARGET TREATMENT TO THE CENTRAL NERVOUS SYSTEM	62/292,157	February 5, 2016	USA
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	PCT/US2017/014914	January 25, 2017	PCT
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	16/075,122	August 2, 2018	USA
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	2017214283	January 25, 2017	Australia
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	3,012,653	January 25, 2017	Canada
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	17747935.9	January 25, 2017	Europe
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	19123784.1	January 25, 2017	Hong Kong
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	260954	January 25, 2017	Israel
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	2018-560432	January 25, 2017	Japan
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	744285	January 25, 2017	New Zealand
INJECTION OF SINGLE-STRANDED OR SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS 9 INTO THE CEREBROSPINAL FLUID	2018/04838	January 25, 2017	South Africa